Magnetic stimulation reduces involuntary jerks
- Trial ID
- NCT06570824
- Official Title
- Network Based Repetitive Transcranial Magnetic Stimulation (rTMS) as an Intervention for Levodopa-induced Dyskinesia (LID) in Parkinson's Disease (PD)
- Goal
- Magnetic stimulation reduces involuntary jerks
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Danish Research Centre for Magnetic Resonance
- Study Type
- INTERVENTIONAL
- Enrollment
- 68 participants
- Conditions
- Dyskinesia, Drug-Induced, Parkinson Disease
- Interventions
- active TMS, sham TMS
Plain-Language Summary
They're testing whether targeted magnetic stimulation can reduce the involuntary jerks and writhing that happen at levodopa's peak, the peak-of-dose dyskinesia that many people with Parkinson's find disabling. The approach uses network-based repetitive transcranial magnetic stimulation, delivering brief magnetic pulses to modulate overactive brain circuits that drive dyskinesia, comparing active versus sham stimulation; it does not change your levodopa but aims to dampen the abnormal motor signals. The trial seeks people aged 18 to 80 with clinically established or probable Parkinson's who have peak-of-dose dyskinesia and have been on stable Parkinson medications for at least four weeks. People with epilepsy or seizure risk, certain psychiatric conditions, regular benzodiazepine or opioid use, use of antipsychotics, Donepezil or GABAergic drugs, MRI contraindications, or women who are pregnant or not using contraception are excluded, and participants must consent to be informed about any incidental health findings.
Locations
- DRCMR, Hvidovre, Denmark
Frequently Asked Questions
- What is this trial testing?
- This trial is studying active TMS. They're testing whether targeted magnetic stimulation can reduce the involuntary jerks and writhing that happen at levodopa's peak, the peak-of-dose dyskinesia that many people with Parkinson's find disabling. The approach uses network-based repetitive transcranial magnetic stimulation, delivering brief magnetic pulses to modulate overactive brain circuits that drive dyskinesia, comparing active versus sham stimulation; it does not change your levodopa but aims to dampen the abnormal motor signals. The trial seeks people aged 18 to 80 with clinically established or probable Parkinson's who have peak-of-dose dyskinesia and have been on stable Parkinson medications for at least four weeks. People with epilepsy or seizure risk, certain psychiatric conditions, regular benzodiazepine or opioid use, use of antipsychotics, Donepezil or GABAergic drugs, MRI contraindications, or women who are pregnant or not using contraception are excluded, and participants must consent to be informed about any incidental health findings.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 9 months.